Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company listed on NASDAQ under the ticker BDRX, successfully conducted its Annual General Meeting (AGM) on June 13, 2024. During the meeting, all resolutions presented to the shareholders were approved. The company, which focuses on developing innovative products for diseases with unmet medical needs, highlighted its lead development programs, including eRapa for Familial Adenomatous Polyposis and Non Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for rare/orphan brain cancer. Biodexa's proprietary drug delivery technologies aim to improve the bio-delivery and bio-distribution of medicines. The full details of the resolutions passed at the AGM are available on the company's website. The company's headquarters and R&D facility are located in Cardiff, UK.

Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company listed on NASDAQ under the ticker BDRX, successfully conducted its Annual General Meeting (AGM) on June 13, 2024. During the meeting, all resolutions presented to the shareholders were approved. The company, which focuses on developing innovative products for diseases with unmet medical needs, highlighted its lead development programs, including eRapa for Familial Adenomatous Polyposis and Non Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for rare/orphan brain cancer. Biodexa's proprietary drug delivery technologies aim to improve the bio-delivery and bio-distribution of medicines. The full details of the resolutions passed at the AGM are available on the company's website. The company's headquarters and R&D facility are located in Cardiff, UK.